Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Completed · Phase 3 · Has a placebo group

Conditions studied: Bronchiectasis

In brief

The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.

Key facts

Study ID

NCT01764841

Run by

Bayer

People needed

416

Starts

2013-05-02

Expected to finish

2016-03-09

Last updated by the study team

2018-01-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a proven and documented diagnosis of non Cystic Fibrosis (CF) idiopathic or post infectious bronchiectasis
• Stable pulmonary status and stable regimen of standard treatment at least for the past 4 weeks

You may not qualify if…

• Forced expiratory volume in 1 second (FEV1) <30% or >90% predicted
• Active allergic bronchopulmonary aspergillosis
• Active and actively treated non tuberculosis mycobacterial (NTM) infection or tuberculosis
• Primary diagnosis of Chronic obstructive pulmonary disease (COPD)

Where it is running

• Study site — Flagstaff, Arizona, United States
• Study site — Phoenix, Arizona, United States
• Study site — Scottsdale, Arizona, United States
• Study site — Fort Smith, Arkansas, United States
• Study site — Los Angeles, California, United States
• Study site — Torrance, California, United States
• Study site — Ventura, California, United States
• Study site — Farmington, Connecticut, United States
• Study site — Waterbury, Connecticut, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Celebration, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Weston, Florida, United States
• Study site — Winter Park, Florida, United States
• Study site — Lawrenceville, Georgia, United States
• Study site — Marietta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Michigan City, Indiana, United States
• Study site — Hazard, Kentucky, United States
• Study site — Chesterfield, Missouri, United States
• Study site — Summit, New Jersey, United States
• Study site — New Hyde Park, New York, United States
• Study site — New York, New York, United States
• Study site — Jasper, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.